{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T12:00:38Z","timestamp":1788091238229,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.semarthrit.2020.01.002","type":"journal-article","created":{"date-parts":[[2020,1,11]],"date-time":"2020-01-11T11:00:11Z","timestamp":1578740411000},"page":"458-462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: A comprehensive review"],"prefix":"10.1016","volume":"50","author":[{"given":"S.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.L.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2020.01.002_bib0001","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s00393-018-0565-8","article-title":"[Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment]","volume":"77","author":"Hornig","year":"2018","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0002","first-page":"683","article-title":"Cardiac function in patients with polymyositis or dermatomyositis: a three-dimensional speckle-tracking echocardiography study","volume":"34","author":"Zhong","year":"2018","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0003","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.det.2018.07.006","article-title":"Connective tissue disease: current concepts","volume":"37","author":"Fernandez","year":"2019","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0004","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archdermatol.2009.328","article-title":"Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota","volume":"146","author":"Bendewald","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0005","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/bjd.16230","article-title":"Dermatomyositis: a slow path towards targeted therapies or will conventional therapies prevail?","volume":"179","author":"Piguet","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0006","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11926-014-0465-0","article-title":"Amyopathic dermatomyositis: definitions, diagnosis, and management","volume":"16","author":"Bailey","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0007","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jaut.2013.11.005","article-title":"The clinical features, diagnosis and classification of dermatomyositis","volume":"48-49","author":"Iaccarino","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0008","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jaad.2010.10.016","article-title":"Quality of life in dermatomyositis","volume":"65","author":"Goreshi","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0009","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.15278","article-title":"Expanding the use of the cutaneous dermatomyositis area and severity index (CDASI) to nondermatologists","volume":"176","author":"Kurtzman","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0010","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2133.2008.08711.x","article-title":"Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis","volume":"159","author":"Klein","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0011","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1553-2712.2000.tb02249.x","article-title":"Research fundamentals: selection and development of clinical outcome measures","volume":"7","author":"Singer","year":"2000","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0012","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2133.2007.08342.x","article-title":"Development and validation of the dermatomyositis skin severity index","volume":"158","author":"Carroll","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0013","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/rheumatology\/kem179","article-title":"The cutaneous assessment tool: development and reliability in juvenile idiopathic inflammatory myopathy","volume":"46","author":"Huber","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0014","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/jid.2011.440","article-title":"Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM","volume":"132","author":"Goreshi","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0015","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/art.23313","article-title":"Alternative scoring of the cutaneous assessment tool in juvenile dermatomyositis: results using abbreviated formats","volume":"59","author":"Huber","year":"2008","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0016","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1191\/096120399680411416","article-title":"Responsiveness and sensitivity to change of SLE disease activity measures","volume":"8","author":"Corzillius","year":"1999","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0017","first-page":"2078","article-title":"Small changes in outpatients lupus activity are better detected by clinical instruments than by laboratory tests","volume":"22","author":"Fortin","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0018","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2133.2009.09521.x","article-title":"Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument","volume":"162","author":"Yassaee","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0019","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bjd.13915","article-title":"Validation of the cutaneous dermatomyositis disease area and severity index: characterizing disease severity and assessing responsiveness to clinical change","volume":"173","author":"Anyanwu","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0020","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bjd.15140","article-title":"The reliability of the cutaneous dermatomyositis disease area and severity index (CDASI) among dermatologists, rheumatologists and neurologists","volume":"176","author":"Tiao","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0021","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/bjd.15596","article-title":"Evaluation of the reliability of the cutaneous dermatomyositis disease area and severity index and the cutaneous assessment tool-binary method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists","volume":"177","author":"Tiao","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0022","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/bjd.13167","article-title":"Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life","volume":"172","author":"Robinson","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0023","first-page":"1793","article-title":"Examining cutaneous disease activity as an outcome measure for clinical trials in dermatomyositis","volume":"80","author":"Gaffney","year":"2018","journal-title":"Arthr Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0024","article-title":"Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis","author":"Ahmed","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0025","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jaad.2017.10.022","article-title":"Cutaneous dermatomyositis disease course followed over time using the cutaneous dermatomyositis disease area and severity index","volume":"79","author":"Chansky","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0026","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2017.3758","article-title":"Factors associated with clinical remission of skin disease in dermatomyositis","volume":"154","author":"Wolstencroft","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0027","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijwd.2017.05.001","article-title":"The systemic management of cutaneous dermatomyositis: results of a stepwise strategy","volume":"3","author":"Anyanwu","year":"2017","journal-title":"Int J Womens Dermatol"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0028","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2230.2011.04188.x","article-title":"Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions","volume":"37","author":"Hornung","year":"2012","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0029","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","article-title":"Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment","volume":"152","author":"Kurtzman","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0030","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1136\/annrheumdis-2018-eular.3531","article-title":"A phase 2 study of safety and efficacy of lenabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis (abstract)","volume":"77","author":"Werth","year":"2018","journal-title":"Ann Rheumatic Dis"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0031","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/gene.2011.61","article-title":"Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis","volume":"13","author":"Greenberg","year":"2012","journal-title":"Genes Immun"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0032","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2020.01.002_bib0033","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/bjd.17079","article-title":"Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis","volume":"179","author":"Chen","year":"2018","journal-title":"Br J Dermatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220300020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220300020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:02:55Z","timestamp":1758733375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017220300020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0049017220300020"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.01.002","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}